CAJ | 학술논문

目的：观察克拉屈滨联合阿糖胞苷治疗朗格汉斯细胞组织细胞增生症(LCH)的疗效,探讨克拉屈滨治疗 LCH 的机制和适应证范围。方法选取 LCH 使用克拉屈滨联合阿糖胞苷治疗患儿1例,收集临床资料和转归,进行分析。结果经4个疗程克拉屈滨联合阿糖胞苷治疗,LCH 患儿临床症状好转,无疾病活动表现。药物不良反应主要是骨髓抑制,每疗程均发生Ⅲ~Ⅳ级血液系统不良反应。结论克拉屈滨在儿童复发及难治性 LCH 中,是极具潜力的治疗药物之一,对难治复发患者缓解率高,不良反应及远期疗效尚有待观察。但从该药物的作用机制及目前临床经验分析,具有良好前景。
목적：관찰극랍굴빈연합아당포감치료랑격한사세포조직세포증생증(LCH)적료효,탐토극랍굴빈치료 LCH 적궤제화괄응증범위。방법선취 LCH 사용극랍굴빈연합아당포감치료환인1례,수집림상자료화전귀,진행분석。결과경4개료정극랍굴빈연합아당포감치료,LCH 환인림상증상호전,무질병활동표현。약물불량반응주요시골수억제,매료정균발생Ⅲ~Ⅳ급혈액계통불량반응。결론극랍굴빈재인동복발급난치성 LCH 중,시겁구잠력적치료약물지일,대난치복발환자완해솔고,불량반응급원기료효상유대관찰。단종해약물적작용궤제급목전림상경험분석,구유량호전경。
Objective Explore the chemotherapy of recurrent Langerhans cell histiocytosis (LCH) of high risk in children with cladribine and cytarabine. Method Observe the clinical manifestation of one child with relapsed multi-system LCH and the response to 4 courses of cladribine/ cytarabine, and review the related literature. Rsult The pa-tient achieved complete remission and had no sign of disease reactivation for 15 months of follow-up, and her diabe-tes insipidus was improved since the first course of therapy. The main side effect is Ⅳ degree of hematologic toxici-ty. Conclution Cladribine is active and well-tolerated in refractory high risk LCH, though there is still much room for further study.